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Oral antenatal corticosteroids evaluated in fetal sheep
Augusto F. Schmidt1,6, Alan H. Jobe1, Paranthaman S. Kannan1, James P. Bridges1, John P. Newnham2, Masatoshi Saito2,3,
Haruo Usuda2,3, Yusaku Kumagai3, Erin L. Fee2, Michael Clarke4 and Matthew W. Kemp2,3,5
BACKGROUND: The use of antenatal corticosteroids (ACS) in low-resource environments is sporadic. Further, drug choice, dose,
and route of ACS are not optimized. We report the pharmacokinetics and pharmacodynamics of oral dosing of ACS using a preterm
sheep model.
METHODS: We measured pharmacokinetics of oral betamethasone-phosphate (Beta-P) and dexamethasone-phosphate (Dex-P)
using catheterized pregnant sheep. We compared fetal lung maturation responses of oral Beta-P and Dex-P to the standard
treatment with 2 doses of the i.m. mixture of Beta-P and betamethasone-acetate at 2, 5, and 7 days after initiation of ACS.
RESULTS: Oral Dex-P had lower bioavailability than Beta-P, giving a lower maximum maternal and fetal concentration. A single oral
dose of 0.33 mg/kg of Beta-P was equivalent to the standard clinical treatment assessed at 2 days; 2 doses of 0.16 mg/kg of oral
Beta-P were equivalent to the standard clinical treatment at 7 days as assessed by lung mechanics and gas exchange after preterm
delivery and ventilation. In contrast, oral Dex-P was ineffective because of its decreased bioavailability.
CONCLUSION: Using a sheep model, we demonstrate the use of pharmacokinetics to develop oral dosing strategies for ACS. Oral
dosing is feasible and may facilitate access to ACS in low-resource environments.
Pediatric Research (2019) 86:589–594; https://doi.org/10.1038/s41390-019-0519-0
INTRODUCTION
Antenatal corticosteroids (ACS) are considered by the World
Health Organization to be the most effective underutilized
treatment available to improve outcomes for fetuses at risk for
preterm delivery.1 Despite being used clinically for nearly 50 years,
the corticosteroid, dose, treatment interval, and route of treatment
remain largely unexplored.2 While ACS are given to >80% of at-risk
pregnancies in advanced clinical care settings, their use is low, and
there are questions about efficacy and safety in low medical
resource environments where the majority of the mortality from
prematurity occurs.3,4 An optimal ACS therapy for low-resource
environments should expose the mother and fetus to the lowest
effective dose for the shortest time using a stable, readily available
and inexpensive preparation.5
The current standard-of-care treatments may be exposing the
fetus to more corticosteroids than necessary.6,7 ACS therapy is
usually given as 12 mg of a 1:1 mixture of betamethasone-
phosphate (Beta-P) and betamethasone-acetate (Beta-Ac) intra-
muscular (i.m.) at the recognition of preterm labor and a second
12mg dose 24 h later. Another commonly used treatment is
dexamethasone-phosphate (Dex-P) given as four 6 mg maternal i.
m. injections given at 12-h intervals. Data from sheep and non-
human primate models of pregnancy demonstrate that the slowly
soluble Beta-Ac component alone is sufficient to induce fetal lung
maturation.7,8 The Beta-Ac treatment eliminates the two high
maternal and fetal peak Beta levels resulting from the soluble
Beta-P in the combined formulation and the four high Dex peaks
resulting from the Dex-P treatment. With pharmacokinetic (PK)
measurements of Beta-Ac and maternal infusion experiments with
Beta-P, we have estimated the fetal blood target range of Beta to
cause fetal lung maturation be about 1–4 ng/mL for an exposure
duration of about 48 h.7–9
The clinical ACS treatments use i.m. maternal injections for drug
delivery. However, Beta-P and Dex-P are routinely given orally for
multiple indications.10 Therefore, we have evaluated the PKs of
oral Beta-P and oral Dex-P and tested several dosing schedules for
lung maturation in preterm pregnant sheep. These are proof-of-
principle experiments for our ultimate goal to optimize ACS
treatments in low-resource environments.
METHODS
Experiments with sheep
The animal experiments were performed in Perth, WA, following
review and approval by the Animal Ethics Committee, University
of Western Australia and Murdoch University (approval numbers
RA/3/100/1378 and R3056/18, respectively). All pregnant sheep
were from a single supplier and experiments were performed in
July 2017 and July 2018 during the normal delivery season. These
experiments used the following corticosteroids: a mixture of
3.9 mg Beta-P and 3.0 mg Beta-Ac per ml (Celestone Chronodose
Merck Sharp & Dohme, Macquarie Park, NSW, Australia) for the
i.m. maternal standard clinical treatment or oral treatment groups
given Beta-P (4.0 mg/ml; Betnesol, Focus Pharmaceuticals, Lon-
don, UK) or Dex-P (4.0 mg/ml, Hospira Australia, Melbourne,
Australia).
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Oral Beta-P and Dex-P PK studies
Beta and Dex concentrations in maternal and fetal plasma were
measured as described previously.11 Using an aseptic procedure
performed under general anesthesia, double lumen catheters
were inserted into fetal and maternal jugular veins and secured to
the back of the ewe. Ewes were recovered for 24 h before being
orally dosed with 0.33 mg/kg Beta-P or 0.33 mg/kg Dex-P in a total
volume of 20 mL of normal saline. The ewes were restrained for
oral treatments and the drug was administered with a syringe
inserted in the ewe’s mouth. The ewes promptly swallowed the
drug upon administration. The bioavailability of liquid and tablet
formulations of Dex is equivalent.12 Maternal and fetal blood
samples were drawn and the plasma was recovered and snap
frozen until analysis as before.11 Beta and Dex plasma standards
were run in triplicate for four biological replicates in separate
maternal and fetal pairs. Intra-assay coefficient of variation
values for mid-range (100 ng/mL per mL plasma) and low-range
(12.5 ng/mL) plasma standards were 0.74% and 1.3%, respectively.
The assay sensitivity for Dex and Beta is 1 ng/mL with a signal-to-
noise ratio of 10:1. Maternal and fetal Beta and Dex concentrations
were fitted to a non-compartmental model (extravascular input)
using PKSOLVER.13
ACS efficacy studies
These studies were exploratory evaluations of oral dosing of Beta-
P and Dex-P performed before the PK data for Dex were available
as we assumed comparable PK for Beta and Dex. Ewes with a
single fetus received an i.m. injection of 150mg medroxyproges-
terone acetate at 105 days gestational age (Depo-Ralovera; Pfizer,
West Ryde, NSW, Australia). The negative saline controls were
given maternal i.m. or oral saline. Positive controls were treated
with the clinical drug as two doses of Beta-P+ Beta-Ac 0.25 mg/kg
maternal weight separated by 24 h. Based on the bioavailability of
oral Beta-P and Dex-P in other species of about 80% of i.m.
administration, we increased our initial oral test doses of Beta-P
and Dex-P to 0.33 mg/kg in 20 ml of saline for comparison with
the clinical dose.14 The treatment groups, doses, and treatment
schedules are listed in Table 1. Groups were delivered at
120–123 days gestation at 2, 5, or 7 days after initiation of the
treatments to evaluate the lung maturational responses.7 The
delivery gestation at 120–123 was selected to reliably have fetuses
in the early phase of alveolarization and prior to an increase in
surfactant (Term= 150 days).15
Ventilation of prematurely delivered lambs
Ewes were given an intravenous bolus of midazolam (0.5 mg/kg)
and ketamine (10 mg/kg) and a spinal injection of lidocaine
(60 mg in 3mL) immediately prior to delivery. Lambs were
then surgically delivered, given an i.m. injection of ketamine
(10 mg/kg), and intubated by tracheostomy. The lambs were
ventilated for 30 min using Acutronic Fabian® infant ventilators
(Acutronic Medical Systems, Hirzel, Switzerland).7 The ventilator
delivered heated and humidified 100% oxygen, maximal peak
inspiratory pressures of 35–40 cm H2O, and a positive
end expiratory pressure of 5 cm H2O. The respiratory rate was
50 breaths/min, and the inspiratory time was 0.5 s. A maximum
tidal volume of 8 mL/kg was targeted by adjusting peak
inspiratory pressure only. The investigators responsible for lamb
ventilations were blinded to treatment groups.
Arterial blood pH, pO2, and pCO2 were measured from blood
drawn from an umbilical artery catheter. Ventilation data
(compliance, tidal volume, peak inspiratory pressure) were
recorded at 10, 20, and 30min.7 Ventilation efficiency index (VEI)
was calculated as VEI= 3800/[respiratory rate × peak inspiratory
pressure− positive end expiratory pressure × pCO2 (mmHg)].
16
Lambs and ewes were euthanized while anesthetized with an
intravenous overdose of sodium pentobarbital. Lamb necropsy
was performed as follows: lambs were weighed, and the chest
was opened to measure lung compliance with a static
pressure–volume curve to 40 cm H2O pressure.
7 The lungs were
then removed and weighed and tissue samples were collected. An
alveolar lavage was performed on the left lung with samples
saved for measurement of saturated phosphatidylcholine (SatPC)
as previously reported.17
mRNA measurements for lung maturation
Frozen lung tissues were processed for RNA extraction with TRIzol
(Invitrogen, Carlsbad, CA). Reverse transcription reactions were
performed using the Verso cDNA kits (Thermo Scientific, Waltham,
MA) to produce single-strand cDNA. Gene markers of pulmonary
maturation—surfactant protein A (SFTPA), surfactant protein B
(SFTPB), sodium channel epithelial 1 alpha subunit (SCNN1A), ATP-
binding cassette subfamily A member 3 (ABCA3), and aquaporin 5
(AQP5)—were amplified using sheep-specific primers and Taqman
probes (Applied Biosystems, Foster City, CA). Gene expression was
normalized for the ribosomal protein 18s mRNA. Data are
expressed as fold change relative to negative controls.
Statistical analysis
Statistical analyses were performed using IBM SPSS for Windows
(Armonk, NY). Data were tested for distribution and variance.
Mean differences between normally distributed data were tested
for significance by two-tailed t tests for differences between two
groups and with one-way analysis of variance for multiple
Table 1. Description of study groups for oral dosing
Group Treatment N Gestational
age, days
M/F BW, kg Cord blood pH pCO2
Negative control I.m. or oral saline 2, 5, or 7 days before delivery 25 122 ± 1 14/11 2.7 ± 0.3 7.35 ± 0.06 52 ± 8
Clinical treatment 2 days 0.25mg/kg Beta-P+ Beta-Ac at 0 and 24 h 10 122 ± 0.5 3/7 2.6 ± 0.3 7.35 ± 0.07 50 ± 7
Clinical treatment 5 days 0.25mg/kg Beta-P+ Beta-Ac at 0 and 24 h 8 122 ± 0.8 2/4a 2.7 ± 0.2 7.36 ± 0.03 51 ± 5
Clinical treatment 7 days 0.25mg/kg Beta-P+ Beta-Ac at 0 and 24 h 8 122 ± 1.6 2/6 2.9 ± 0.3 7.34 ± 0.04 51 ± 6
Oral Beta-P 2 days 0.33mg/kg Beta-P at 0 h 9 122 ± 0.5 2/7 2.4 ± 0.1 7.36 ± 0.04 48 ± 6
Oral Beta-P 5 days 0.33mg/kg Beta-P at 0 h 10 123 ± 0.5 3/7 2.8 ± 0.3 7.36 ± 0.05 50 ± 5
Oral Beta-P 7 days 0.16mg/kg Beta-P at 0 and 24 h 9 123 ± 0 4/5 2.9 ± 0.3 7.34 ± 0.04 51 ± 4
Oral Dex-P 5 days—1 dose 0.33mg/kg Dex-P×1 at 0 h 10 121 ± 0.3 6/4 2.7 ± 0.3 7.38 ± 0.03 49 ± 5
Oral Dex-P 5 days—2 doses 0.33mg/kg Dex-P at 0 and 24 h 10 122 ± 0.5 8/2 2.8 ± 0.2 7.35 ± 0.03 48 ± 3
Oral Dex-P 7 days—3 doses 0.33mg/kg Dex-P at 0, 12 and 24 h 7 121 ± 0 4/3 2.6 ± 0.1 7.32 ± 0.02 57 ± 3
Beta-AC betamethasone-acetate, Beta-P betamethasone-phosphate, BW birth weight, Dex-P dexamethasone-phosphate, F female, I.m. intramuscular, M male
aSex not recorded in two animals
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comparisons (p= 0.05). Dunnett’s post-test was used to perform
multiple post hoc comparisons. For non-parametric data,




We gave oral doses of 0.33 mg/kg Beta-P and Dex-P to
compensate for the presumed decreased bioavailability to about
80% of our i.m. clinical dose of 0.25 mg/kg Beta-P plus Beta-Ac.
However, there is no information available about oral absorption
or bioavailability of steroids in sheep. The curves in Fig. 1
demonstrate that oral Beta-P slightly reduced the high peak of
Beta after the clinical dose and had a comparable maternal
exposure over 24 h. Maternal area under the curve (AUC0–t) values
for oral Dex-P and oral Beta-P were 320.6 and 1222.6 ng/mL/h,
respectively. Fetal AUC0–t values for oral Dex-P and Beta-P were
35.5 and 143.9 ng/mL/h, respectively. The oral Beta-P had a later
and slightly lower peak exposure in the fetus, than achieved
with clinical dosing, and the Beta level remained in or above the
target zone of 1–4 ng/ml for 24 h. Compared to oral Beta
dosing, maximum maternal (73.8 vs 20.7 ng/mL) and fetal (8.4 vs
2.5 ng/mL) Dex plasma levels were significantly lower and fell below
the target 1–4 ng/mL range much more rapidly (Fig. 1). The maternal
and fetal Beta plasma levels from the clinical drug after 6–8 h are
from the Beta-Ac because of the more rapid clearance of the Beta-P
component of the drug. The half-life of oral Beta was 3.7 h in the
ewe and 4.6 h in the fetus, with similar values for Dex. The ratio of
maternal to fetal plasma Beta or Dex at maximum concentration was
similar (8:1), which is in keeping with data suggesting that placental
transfer of Beta and Dex is roughly equivalent.
Efficacy studies
We randomized pregnant ewes to negative controls with saline or
positive controls with the i.m. maternal standard clinical
treatments with 0.25 mg/kg Beta-P+ Beta-Ac given at 0 and
24 h. Concurrently, ewes were randomized to 0.33mg/kg oral Dex-
P, 0.33 mg/kg or 0.16 mg/kg oral Beta-P for different numbers of
treatments and time intervals between treatments. All animal
groups were delivered at similar gestational ages with similar birth
weights and cord blood pH and pCO2 values (Table 1). The
ventilator variables at 30 min of ventilation demonstrate improve-
ments relative to negative controls for blood pH and pCO2 and
with better compliances for the standard clinical treatment for
deliveries at 2, 5, and 7 days (Table 2). The pO2 values were highly
variable. Figure 2 gives values for maximal static lung gas volumes
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Fig. 1 Maternal (a) and fetal (b) plasma drug levels after single oral dose of 0.33 mg/kg betamethasone-phosphate (Beta-P) (dashed) or 0.33
mg/kg dexamethasone-phosphate (Dex-P) (dotted line) or 0.25 mg/kg of the standard clinical drug (solid line) in pregnant sheep. Oral Dex
had decreased absorption compared to oral Beta and resulted in a lower maximal concentration and trough. A single dose of 0.33 mg/kg of
oral Beta kept fetal drug levels above the target range (shaded area) for 24 h. The curves for the clinical drug were previously reported9









Control 38 ± 2 4.4 ± 1.3 0.09 ± 0.03 6.86 ± 0.09 128 ± 23 36 ± 28
Clinical treatment 2 days 35 ± 5 7.2 ± 0.8a 0.19 ± 0.08a 7.16 ± 0.13a 56 ± 23a 61 ± 16
Clinical treatment 5 days 35 ± 6 7.7 ± 0.6a 0.24 ± 0.06a 7.29 ± 0.17a 50 ± 15a 112 ± 160a
Clinical treatment 7 days 33 ± 3a 5.6 ± 2.3 0.21 ± 0.11a 7.10 ± 0.27a 94 ± 51a 84 ± 74
Oral Beta-P 2 days 36 ± 4 7.9 ± 0.7a 0.21 ± 0.06a 7.20 ± 0.11a 60 ± 12a 112 ± 60a
Oral Beta-P 5 days 40 ± 1 6.2 ± 1.8a 0.14 ± 0.06a 7.07 ± 0.21a 92 ± 42a 55 ± 34
Oral Beta-P 7 days 32 ± 4a 7.2 ± 0.7a 0.28 ± 0.07a 7.24 ± 0.10a 56 ± 15a 175 ± 160a
Oral Dex-P 5 days × 1 dose 40 ± 0 5.5 ± 1.4 0.11 ± 0.06 7.01 ± 0.15a 104 ± 38 36 ± 16
Oral Dex-P 5 days × 2 doses 36 ± 4 7.2 ± 1.6a 0.20 ± 0.07a 7.18 ± 0.17a 62 ± 19a 61 ± 77
Oral Dex-P 7 days × 3 doses 35 ± 0a 3.9 ± 2.0 0.13 ± 0.07 6.91 ± 0.19 126 ± 41 47 ± 37
Beta-AC betamethasone-acetate, Beta-P betamethasone-phosphate, Dex-P dexamethasone-phosphate
ap < 0.05 relative to negative control
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measurement that includes pCO2, ventilation pressure, and rate.
Both these primary outcome measurements for the standard
clinical treatment were significantly improved relative to negative
controls. While there was variability, the standard clinical
treatments were not different at 2, 5, or 7 days. We did not
identify differences in response to corticosteroids by gender,
although our study was not powered to detect such differences.
The oral Beta-P treatment given as 1 dose and evaluated at
2 days had similar improvements in compliance, pCO2, V40, and
VEI as did the standard clinical treatment at 2 days (Table 2, Fig. 2).
The 1 dose Beta-P effects were not significantly different from
negative controls at 5 days. In contrast, a 2-dose oral Beta-P
treatment separated by 24 h with 0.16 mg/kg Beta-P was
qualitatively the best treatment with the highest compliance,
V40, and VEI measurements at 7 days that were not significantly
different from the standard clinical treatment with 2 doses at
7 days.
The single oral Dex-P treatment evaluated at 5 days was not
different from negative controls, indicating no efficacy (Fig. 3).
Two doses of Dex-P given at 24 h increased all the blood gas
ventilation variables significantly relative to negative controls to
values that approached and were not different from the standard
clinical treatment. In contrast, a 3-dose treatment at 12-h intervals
and evaluated at 7 days had no significant indicators of improved
lung function relative to negative controls. The increased dosing
did not result in a durable Dex-P effect at 7 days.
Other indications of maturation
In fetal sheep, lung mechanics improve with effective ACS
within 24 h. While mRNA changes are detectable early after
administration of ACS and return to levels similar to negative
controls by about 5 days after treatment, SatPC does not increase
until after about 4 days.18 We analyzed mRNA levels by real-time
PCR at 2 and 5 days after ACS (Fig. 4). At 2 days, oral Beta and
the standard clinical treatment increased the mRNA levels of
SFTPB, SCNN1A, ABCA3, and AQP5. At 5 days, gene levels of
maturation markers had returned to levels similar to negative
controls, except for the levels of SFTPB and ABCA3 after the
standard clinical treatment and ABCA3 after oral Dex-P x1. We
measured SatPC at 7 days after ACS. The standard clinical
treatment and the two doses of Beta-P treatment increased Sat
PC in the alveolar lavages (Fig. 5). In contrast, three doses of Dex-P
given at 12-h intervals did not increase SatPC.
DISCUSSION
As proof of principle, oral dosing of ACS induced fetal lung
maturation equivalently to the two-dose standard clinical treat-
ment with Beta-P+Beta-Ac. However, oral Dex-P and Beta-P differ
strikingly in their absorption and bioavailability in sheep. Peak
maternal and fetal blood levels were measured at about 6–8 h in
sheep. In contrast, oral Dex-P yields shorter times of <2 h to peak
levels in healthy adults and in women being treated with ACS for
the risk of preterm delivery.12,14 Oral and i.m. Dex-P yield similar
biological half-life values and high estimates of bioavailability
ranging from 65% to 100%.14,19 There is very little information
about Beta-P in pregnant women beyond some measurements
with the Beta-P+Beta-Ac combination.20–22 In sheep for equiva-
lent oral doses of 0.33 mg/kg, peak maternal plasma levels of Dex-
























































Fig. 2 Lung compliance and ventilation efficiency of oral betamethasone (Beta) vs the standard clinical treatment. a Lung volume at a
pressure of 40 cmH2O and b ventilation efficiency index (VEI) after oral Beta-phosphate (Beta-P) compared to the standard clinical treatment
in preterm sheep. A single dose of 0.33 mg/kg oral Beta-P increased the V40 and VEI similarly to the standard clinical treatment at 2 days but






















































Fig. 3 Lung compliance and ventilation efficiency of oral dexamethasone (Dex) vs the standard clinical treatment. a Lung volume at a
pressure of 40 cmH2O and b ventilation efficiency index (VEI). A single dose of oral Dex was not as effective as the standard clinical treatment
in improving lung compliance and ventilation efficiency, and the effect was improved when given as 2 doses of oral Dex 24 h apart. The
administration of 3 doses of oral Dex 12 h apart was not effective in producing a lasting effect on lung maturation to 7 days. (*p < 0.05)
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demonstrating greatly decreased bioavailability of Dex than Beta
in sheep after oral administration. The PKs of Beta and Dex clearly
differ for sheep and humans with decreased bioavailability of oral
Dex-P in sheep. Nevertheless, we were able to demonstrate the
principles for oral dosing of ACS. PK studies of Beta-P and Dex-P
comparing i.m. and oral formulations in women are currently
being evaluated (ClinicalTrials.gov Identifier: NCT03668860).
We performed the PK studies of fetal lung responses to ACS
based on the PK information that we had for Beta-P, and we
incorrectly assumed that Dex-P levels would be comparable. We
evaluated a high-dose estimate of the drugs given orally based on
80% bioavailability as a representative value in humans.14 We
previously reported that fetal sheep responded to ACS blood
levels in the range of 1–4 ng/mL based on studies with Beta-Ac
and maternal infusions of Beta-P to target that fetal blood level.9,11
We were also concerned about the durability of the ACS response
if fetal drug level were not maintained for at least 48 h. As the ratio
of the fetal to maternal plasma levels are about 0.1 for Dex or
Beta in sheep, relatively large maternal doses need to be given
to achieve adequate fetal plasma drug levels. In contrast, the fetal-
to-maternal blood level ratios for humans is about 0.5,21
suggesting that lower oral doses should be sufficient for lung
maturation.
Our results support the validity of the estimated minimal fetal
exposure to >1 ng/mL for a lung maturation stimulus. We used the
standard clinical dosing with two doses of 0.25mg/kg Beta-P
+Beta-Ac as the presumed gold standard for a Beta exposure that
will cause fetal lung maturation. The previously reported maternal
and fetal Beta levels cause excessive maternal and fetal drug
exposures for about 8 h, and the second dose should keep Beta
levels in the fetus >1 ng/mL for 48 h (Fig. 1).9,11,23 Our dose of 0.33
mg/kg oral Beta-P resulted in excessive fetal exposures between 4
and 16 h. A single oral Beta treatment induced lung maturation
comparable to the standard clinical 2-dose treatment at 2 but not
at 5 days, presumably because the single dose was not sufficient
for durability to 5 days. However, we tested a 2-dose 24-h
treatment interval with a lower oral dose of 0.16mg/kg, which
should keep fetal Beta levels >1 ng/ml for at least 48 h and cause
lung maturation at 7 days. In contrast, 1 or 2 doses of oral Dex at
0.33mg/kg caused minimal lung maturational responses at 5 days
as did 3 doses at 7 days as anticipated based on the PKs of Dex in
sheep. These detailed PK and pharmacodynamic assessments for
ACS cannot be performed with precision in women at risk of
preterm delivery. The early mRNA changes of maturation markers
after oral Beta were similar to the standard clinical treatment and
consistent with the physiological observation of mechanical lung
improvement with the oral Beta treatment and the increase in
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Fig. 4 mRNA levels of the select genes associated with lung maturation: a Surfactant protein B (SFTPB); b ATP-binding cassette subfamily
























Fig. 5 Saturated phosphatidylcholine (SatPC) concentration in the
bronchoalveolar lavage fluid after treatment of preterm sheep
with oral or intramuscular corticosteroids. Oral betamethasone-
phosphate increased the SatPC concentration equivalently to the
standard clinical treatment, while oral dexamethasone did not; n=
6–7 animals/group (*p < 0.05)
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There is minimal clinical information about oral dosing for ACS.
Egerman and colleagues reported a PK study with oral Dex-P and
used that information for a clinical study that was stopped early
for adverse fetal effects with oral treatment.14,24 The authors
commented that the complications of neonatal sepsis and
intraventricular hemorrhage were much lower than anticipated
in the maternal i.m. Dex group relative to the oral Dex-P and that
further research on oral ACS was warranted. There is no good
explanation about why oral vs i.m. dosing should differ in lung
maturational response if comparable fetal exposures are achieved.
The studies demonstrate that drug characteristics, dose, and
treatment intervals are critical for durable maturational responses
in sheep. Multiple drugs, doses, and dosing intervals are used in
humans without consideration of these variables or validation of
clinical responses. These studies together with our previous
evaluation of i.m. and infusions of Beta provide insight about how
ACS therapy can be optimized. Our proof-of-concept experiments
in sheep demonstrate that oral dosing for ACS is feasible.
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